SciELO - Scientific Electronic Library Online

 
vol.79 número3Adrenarquia precoz y marcadores del síndrome metabólicoSobrevida y morbilidad en recién nacidos que pesaron menos de 1.000 gramos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Links relacionados

Compartilhar


Archivos de Pediatría del Uruguay

versão On-line ISSN 1688-1249

Resumo

DUFORT Y ALVAREZ, Gustavo et al. Trasplante de progenitores hematopoyéticos en pediatría: 10 años de experiencia. Arch. Pediatr. Urug. [online]. 2008, vol.79, n.3, pp.201-209. ISSN 1688-1249.

Summary Background: in Uruguay the survival estimates for pediatric patients with cancer are comparable to those in developed countries. With the aim of improving outcomes in patients with worse prognosis and provide therapeutic options for treating some non malignant diseases, we started a hematopoietic stem cell transplantation (HSCT) program in 1997, with the financial support of the National Resources Fund (Fondo Nacional de Recursos - FNR). Patients and methods: the unit was created at the Asociación Española Hospital and counts with three rooms with a sophisticated isolation system. Isolation measures and guidelines for preventing opportunistic infections were strictly enforced. HSCT indications followed the national FNR guidelines according to recommendations of international groups. International standards were used for the patients management. Results: in 10 years 131 transplants were performed in 129 patients. The 10 year overall survival estimate was 43,9 ± 4,6%. Transplant related mortality was 9,3% and the main cause of death were infections. In allogenic HSCT acute graft versus host disease was the leading cause of death. There were three patients who had hitherto secondary malignancies. Conclusions: the results, as well as past experience in these 10 years are encouraging. The utility of the procedure in many of the pathologies was analyzed and demonstrated. In the future our goal is to offer this treatment to all patients in which the HSCT is indicated, including those with no compatible family donor.

Palavras-chave :  HEMETOPOIETIC STEM CELL TRANSPLANTATION;  BONE MARROW TRANSPLANTATION;  LEUKEMIA, MYELOID, ACUTE;  PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;  LYMPHOMA;  NEOPLASMS;  NEUROBLASTOMA.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons